TapewireFind a company

person · Reporting owner

De Witte Jan

Disclosed activity across 2 companies

Tapewire entity
72558
SEC CIK
0001776929

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707Director · President & CEONovember 01, 2024November 04, 2024
RESMED INCRMD · Entity 2692DirectorNovember 25, 2025November 26, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INTEGRA LIFESCIENCES HOLDINGS CORP

Report date November 01, 2024 · Filed November 04, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,902 Ending reported balance After 2024-11-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-11-01 · Exercise / conversion · Acquired 9,814 · Balance 28,164

F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

Row 2 · 2024-11-01 · Tax withholding · Disposed 4,262 · Balance 23,902

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct120,466 Reported balance After 2024-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-11-01 · Exercise / conversion · Disposed 9,814 · Balance 120,466

F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

Filing footnotes · ownership attribution and instrument terms

F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

RESMED INC

Report date November 25, 2025 · Filed November 26, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
ReMed Common StockSEC Table I · non-derivativeDirect4,261 Reported balance After 2025-11-25 transaction · row 1
1 source row

Row 1 · 2025-11-25 · Sale · Disposed 2,055 · Balance 4,261

F1: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 25, 2025 Filed Nov 26, 2025 19:40 UTC RESMED INC RMD · Entity 2692 SaleReMed Common Stock 2,055 $255.00 $524,025.00
Disclosure

SEC source: 0000943819-25-000181 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,261

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 14:45 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,073 $0.00 $0.00
Disclosure

SEC source: 0000943819-25-000166 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,316

F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

Read SEC document
November 11, 2025 Filed Nov 13, 2025 22:24 UTC RESMED INC RMD · Entity 2692 Tax withholdingReMed Common Stock 76.449 $250.10 $19,119.89
Disclosure

SEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,242

F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024.

Read SEC document
November 11, 2025 Filed Nov 13, 2025 22:24 UTC RESMED INC RMD · Entity 2692 SaleReMed Common Stock 487 $250.25 $121,871.75
Disclosure

SEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,319

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted Feb 03, 2025.

Read SEC document
May 20, 2025 Filed May 22, 2025 14:05 UTC RESMED INC RMD · Entity 2692 SaleReMed Common Stock 2,000 $243.47 $486,940.00
Disclosure

SEC source: 0001127602-25-015264 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,806

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 3, 2025.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:22 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,083 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-027902 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,806

F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 16:49 UTC RESMED INC RMD · Entity 2692 SaleReMed Common Stock 796 $248.81 $198,052.76
Disclosure

SEC source: 0001127602-24-027277 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,723

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024.

Read SEC document
November 01, 2024 Filed Nov 4, 2024 21:33 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 9,814 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,466

Underlying: Common Stock · 9,814 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

F1 · derivative.expiration_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

Read SEC document
November 01, 2024 Filed Nov 4, 2024 21:33 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 4,262 $19.28 $82,171.36
Disclosure

SEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,902

Read SEC document
November 01, 2024 Filed Nov 4, 2024 21:33 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 9,814 $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,164

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.

Read SEC document
May 15, 2024 Filed May 17, 2024 15:27 UTC RESMED INC RMD · Entity 2692 SaleReMed Common Stock 360 $218.29 $78,584.40
Disclosure

SEC source: 0001127602-24-015777 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,519

Read SEC document
May 15, 2024 Filed May 22, 2024 18:51 UTC Amendment RESMED INC RMD · Entity 2692 SaleReMed Common Stock 360 $218.29 $78,584.40
Disclosure

SEC source: 0001127602-24-016231 · form4a.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,519

F1 · kind: Amended to indicate that the transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:30 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 205 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 5

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,280

Underlying: Common Stock · 205 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F3 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F3 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:30 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantRestricted Stock Units · Derivative 41,414 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 4

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,485

Underlying: Common Stock · 41,414 shares

Expires not disclosed

F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:30 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantNon- Qualified Stock Option (right to buy) · Derivative 95,664 $0.00 Strike: $36.22 $0.00
Disclosure

SEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,664

Underlying: Common Stock · 95,664 shares

Expires 2032-03-11

F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2024.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:30 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 205 $36.22 $7,425.10
Disclosure

SEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,350

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:30 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 205 $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:12 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 346 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,071

Underlying: Common Stock · 346 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:12 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 346 $36.73 $12,708.58
Disclosure

SEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,350

Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:12 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 346 $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 18, 2024 Filed Jan 19, 2024 21:43 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 597 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,417

Underlying: Common Stock · 597 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F1 · derivative.exercise_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F1 · derivative.expiration_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

Read SEC document
January 18, 2024 Filed Jan 19, 2024 21:43 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 597 $42.39 $25,306.83
Disclosure

SEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,350

Read SEC document
January 18, 2024 Filed Jan 19, 2024 21:43 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 597 $0.00 $0.00
Disclosure

SEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 16, 2023 Filed Nov 21, 2023 01:25 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,768 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-028090 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,879

F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:27 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 9,814 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-054323 · doc4.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,014

Underlying: Common Stock · 9,814 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023.

F1 · derivative.expiration_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:27 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 4,262 $36.85 $157,054.70
Disclosure

SEC source: 0001209191-23-054323 · doc4.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,350

Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:27 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 9,814 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-054323 · doc4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023.

Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:10 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 PurchaseCommon Stock 7,792 $38.50 $299,985.77
Disclosure

SEC source: 0001209191-23-033676 · doc4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,798

F1 · price: The price shown above represents the weighted average price of the shares purchased. The range of the purchase prices was $38.46 to $38.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 20:20 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 3,842 $52.87 $203,126.54
Disclosure

SEC source: 0001209191-23-018446 · doc4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,006

Read SEC document
March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 205 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-052775 · doc4a.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,828

Underlying: Common Stock · 205 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023.

F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation.

F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation.

F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation.

Read SEC document
March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 205 $52.87 $10,838.35
Disclosure

SEC source: 0001209191-23-052775 · doc4a.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,006

F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023.

Read SEC document
March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 205 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-052775 · doc4a.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:20 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantRestricted Stock Units · Derivative 26,008 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018446 · doc4.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,033

Underlying: Common Stock · 26,008 shares

Expires not disclosed

F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:20 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantNon-Qualified Stock Option (right to buy) · Derivative 63,717 $0.00 Strike: $52.87 $0.00
Disclosure

SEC source: 0001209191-23-018446 · doc4.xml · derivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,717

Underlying: Common Stock · 63,717 shares

Expires 2031-03-10

F1 · derivative.exercise_price: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.

F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.

Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:35 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantCommon Stock 8,848 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009758 · doc4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,848

F1 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 11, 2022 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 11, 2023, the first anniversary of the grant date.

Read SEC document
January 18, 2023 Filed Jan 19, 2023 21:17 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionRestricted Stock Units · Derivative 431 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004012 · doc4.xml · derivative · entry 3

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,025

Underlying: Common Stock · 431 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F1 · derivative.exercise_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

F1 · derivative.expiration_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation.

Read SEC document
January 18, 2023 Filed Jan 19, 2023 21:17 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Tax withholdingCommon Stock 431 $54.78 $23,610.18
Disclosure

SEC source: 0001209191-23-004012 · doc4.xml · nonDerivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
January 18, 2023 Filed Jan 19, 2023 21:17 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 Exercise / conversionCommon Stock 431 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004012 · doc4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 16, 2022 Filed Nov 21, 2022 21:33 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,122 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-026159 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,111

F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date.

Read SEC document
November 01, 2022 Filed Nov 3, 2022 20:10 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantRestricted Stock Units · Derivative 29,441 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-055496 · doc4.xml · derivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,456

Underlying: Common Stock · 29,441 shares

Expires not disclosed

F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:40 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantRestricted Stock Units · Derivative 15,359 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-018841 · doc4.xml · derivative · entry 2

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,015

Underlying: Common Stock · 15,359 shares

Expires not disclosed

F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:40 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantNon-Qualified Stock Option (right to buy) · Derivative 43,199 $0.00 Strike: $65.11 $0.00
Disclosure

SEC source: 0001209191-22-018841 · doc4.xml · derivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,199

Underlying: Common Stock · 43,199 shares

Expires 2030-03-11

F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2022.

Read SEC document
January 18, 2022 Filed Jan 19, 2022 21:40 UTC INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 GrantRestricted Stock Units · Derivative 29,656 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003745 · doc4.xml · derivative · entry 1

De Witte Jan · CIK 0001776929 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,656

Underlying: Common Stock · 29,656 shares

Expires not disclosed

F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Read SEC document
November 18, 2021 Filed Nov 22, 2021 23:53 UTC RESMED INC RMD · Entity 2692 GrantResMed Common Stock 956 $0.00 $0.00
Disclosure

SEC source: 0000943819-21-000034 · primary_doc.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,989

F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date.

Read SEC document
November 11, 2021 Filed Nov 15, 2021 19:03 UTC RESMED INC RMD · Entity 2692 Tax withholdingReMed Common Stock 104 $259.47 $26,984.88
Disclosure

SEC source: 0001127602-21-029093 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,033

F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020.

Read SEC document
November 27, 2020 Filed Nov 30, 2020 20:56 UTC RESMED INC RMD · Entity 2692 Tax withholdingReMed Common Stock 183 $212.11 $38,816.13
Disclosure

SEC source: 0001127602-20-030106 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,137

F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019.

Read SEC document
November 19, 2020 Filed Nov 21, 2020 00:08 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,187 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-029759 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,320

F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date.

Read SEC document
November 21, 2019 Filed Nov 25, 2019 19:06 UTC RESMED INC RMD · Entity 2692 GrantReMed Common Stock 1,727 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-033656 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,133

F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.